新生儿重症监护病房中肾毒性药物组合与急性肾损伤的关联
该研究纳入2007至2016年间在268个新生儿重症监护病房出院、胎龄22-36周、暴露于肾毒性药物组合且具备血清肌酐数据的8286例婴儿,其中1384例(17%)发生急性肾损伤。多变量分析显示脓毒症、较低基线肌酐和联合用药持续时间与急性肾损伤风险增加相关;与庆大霉素+吲哚美辛相比,呋塞米+妥布霉素和万古霉素+哌拉西林-他唑巴坦与急性肾损伤风险降低相关。
要点
- 暴露于肾毒性药物组合的婴儿中,17%发生急性肾损伤。
- 联合用药持续时间越长,急性肾损伤风险越高。
- 与庆大霉素+吲哚美辛相比,呋塞米+妥布霉素和万古霉素+哌拉西林-他唑巴坦与急性肾损伤风险降低相关。
核心结论
- 在接受肾毒性联合治疗的婴儿中,联合用药持续时间越长,发生急性肾损伤的比值越高。
- 与庆大霉素+吲哚美辛相比,呋塞米+妥布霉素和万古霉素+哌拉西林-他唑巴坦与急性肾损伤风险降低相关。
研究设计与样本
- 研究纳入2007至2016年间在268个Pediatrix Medical Group管理的 neonatal intensive care units 出院、胎龄22-36周、出生后≤120天、暴露于肾毒性药物组合且有血清肌酐测量的婴儿。
- 采用多变量logistic回归和Cox回归分析,调整胎龄、性别、出生体重、出生后日龄、种族/民族、脓毒症、呼吸窘迫综合征、基线血清肌酐和联合用药持续时间。
主要发现
- 8286例纳入婴儿中,1384例(17%)发生急性肾损伤。
- 多变量分析中,脓毒症、较低基线肌酐和联合治疗持续时间与急性肾损伤风险增加相关。
- 与庆大霉素+吲哚美辛相比,呋塞米+妥布霉素和万古霉素+哌拉西林-他唑巴坦在多变量和Cox回归模型中均与急性肾损伤风险降低相关。
关键数值与推荐
- 急性肾损伤依据Kidney Disease: Improving Global Outcomes标准的血清肌酐定义。
- 比较的肾毒性药物组合包括:氯噻嗪+布洛芬、氯噻嗪+吲哚美辛、呋塞米+庆大霉素、呋塞米+布洛芬、呋塞米+妥布霉素、布洛芬+螺内酯、万古霉素+哌拉西林-他唑巴坦,均相对于庆大霉素+吲哚美辛。
临床怎么用
- 对接受肾毒性联合治疗的婴儿应关注急性肾损伤风险,尤其是联合用药持续时间较长者。
- 脓毒症和较低基线肌酐可能提示需加强肾功能监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the incidence of acute kidney injury (AKI) in infants exposed to nephrotoxic drug combinations admitted to 268 neonatal intensive care units managed by the Pediatrix Medical Group. STUDY DESIGN: We included infants born at 22-36 weeks gestational age, ≤120 days postnatal age, exposed to nephrotoxic drug combinations, with serum creatinine measurements available, and discharged between 2007 and 2016. To identify risk factors associated with a serum creatinine definition of AKI based on the Kidney Disease: Improving Global Outcomes criteria, we performed multivariable logistic and Cox regression adjusting for gestational age, sex, birth weight, postnatal age, race/ethnicity, sepsis, respiratory distress syndrome, baseline serum creatinine, and duration of combination drug exposure. The adjusted odds of AKI were determined relative to gentamicin + indomethacin for the following nephrotoxic drug combinations: chlorothiazide + ibuprofen; chlorothiazide + indomethacin; furosemide + gentamicin; furosemide + ibuprofen; furosemide + tobramycin; ibuprofen + spironolactone; and vancomycin + piperacillin-tazobactam. RESULTS: Among 8286 included infants, 1384 (17%) experienced AKI. On multivariable analysis, sepsis, lower baseline creatinine, and duration of combination therapy were associated with increased odds of AKI. Furosemide + tobramycin and vancomycin + piperacillin-tazobactam were associated with a decreased risk of AKI relative to gentamicin + indomethacin in both the multivariable and Cox regression models. CONCLUSIONS: In this cohort, infants receiving longer durations of nephrotoxic combination therapy had an increased odds of developing AKI.
引用
- Salerno SN, Liao Y, Jackson W, et al. Association between Nephrotoxic Drug Combinations and Acute Kidney Injury in the Neonatal Intensive Care Unit. J Pediatr. 2020. PMID: 32818481. doi:10.1016/j.jpeds.2020.08.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。